Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted EBITDA Margin of -44419.37% for Q2 2026, up 97785.97 percentage points from -142205.33% a year earlier and up 37884.18 percentage points from the prior quarter.
Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Viridian Therapeutics, Inc.\DE was -568.97%, up 121103.82 percentage points year-over-year; for FY2025, it came in at -512.21%, up 98327.19 percentage points from FY2024.
- Annual EBITDA Margin shows a five-year change of +9977.41 percentage points (FY2020 to FY2025).
- In prior years, Viridian Therapeutics, Inc.\DE's EBITDA Margin was -98839.40% in FY2024 (-17970.61 pp), -80868.79% in FY2023 (-73306.49 pp), -7562.30% in FY2022 (-4875.57 pp) and -2686.74% in FY2021 (+7802.88 pp).
- Quarterly EBITDA Margin has run from a low of -142205.33% in Q2 2025 to a high of -56.54% in Q3 2025 over five years.
- On a year-over-year basis, EBITDA Margin has increased in each of the last four quarters, with an average year-over-year change of +15983.69 percentage points over the last eight quarters.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q4 2021, with a gain of 154107.18 percentage points; the weakest was Q2 2023, with a drop of 70616.88 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was -82303.55% (Q1 2026), -92870.45% (Q4 2025) and -56.54% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 39.10% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.33 Bn | 2.33 Bn | - | -44,419.37% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44,419.37% |
| Mar 31, 2026 | -82,303.55% |
| Dec 31, 2025 | -92,870.45% |
| Sep 30, 2025 | -56.54% |
| Jun 30, 2025 | -142,205.33% |
| Mar 31, 2025 | -130,206.94% |
| Dec 31, 2024 | -121,318.06% |
| Sep 30, 2024 | -96,918.60% |
| Jun 30, 2024 | -100,062.50% |
| Mar 31, 2024 | -77,433.33% |
| Dec 31, 2023 | -99,066.67% |
| Sep 30, 2023 | -70,956.94% |
| Jun 30, 2023 | -82,143.06% |
| Mar 31, 2023 | -73,844.90% |
| Dec 31, 2022 | -46,595.24% |
| Sep 30, 2022 | -2,487.28% |
| Jun 30, 2022 | -11,526.17% |
| Mar 31, 2022 | -11,967.13% |
| Dec 31, 2021 | -13,574.30% |
| Sep 30, 2021 | -6,780.77% |
Viridian Therapeutics, Inc.\DE EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=VRDN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "VRDN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=VRDN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();